These findings suggest an involvement of EGFR signalling pathway in canine primary lung cancer, a negative prognostic significance of protein overexpression and its potential implication in air pollution carcinogenesis.

Egfr mutations with amino acid substitution were observed in exons 18 and 21 in X-ray-induced lung tumors.

EGFRvIII expressed in human tumors is phosphorylated and hence activated; sustained activation of EGFRvIII is implicated in the pathogenesis of non-small cell lung cancers

Overexpression of EGFR is associated with recurrent non-small cell lung cancer

A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib.

somatic mutations of EGFR were found in 15 of 58 non-small cell lung cancer tumors from Japan and 1 of 61 from the United States; EGFR mutations may predict sensitivity to gefitinib

mutant EGFRs selectively transduce survival signals on which nonsmall cell lung cancers become dependent

serum epidermal growth factor receptor and HER2 have roles in response of advanced non-small cell lung cancer to chemotherapy

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness

In addition to EGFR mutations, other factors in non-small cell lung carcinoma cells, such as high expression of ErbB family members, may constitutively activate AKT and sensitize cells to EGFR inhibitors.

EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in non-small cell lung cancers.

mutations in either the EGFR TK domain or the KRAS gene can lead to lung cancer pathogenesis. EGFR TK domain mutations are the first molecular change known to occur specifically in never smokers.

mutations in the tyrosine kinase domain of the epidermal growth factor receptor is associated with non-small cell lung cancer

data suggest that mutations of epidermal growth factor receptor (EGFR) and K-RAS genes might separately, but not cooperatively, contribute to lung adenocarcinoma pathogenesis

Using the LightCycler PCR assay, the EGFR L858R mutation status might correlate with gender, pathologic subtypes, and gefitinib sensitivity of lung cancers.

analysis of EGFR mutations in malignant pleural effusion of non-small cell lung cancer (case report)

Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells

EGFR mutation plays an important role in pathogenesis of lung adenocarcinoma

EGFR expression status in lung cancer correlates with its mutation.

Acquisition of resistance to tyrosine kinase inhibitors in non-small cell lung cancer is linked to a specific secondary somatic mutation, EGFR T790M.

data describe percentage of bone marrow cells expressing receptors for interleukin-1, platelet-derived growth factor, fibroblast growth factor, transforming growth factor-beta, epidermal growth factor and c-Fos and c-Myc in untreated lung & breast cancer

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in non-small cell lung cancer

EGFR mutations may contribute to the development of bronchioloaveolar carcinoma and are one of the early genetic alterations in multistage carcinogenic processes of lung adenocarcinoma

Epidermal growth factor receptor gene mutation is associated with adenocarcinomas of the lung

EGFR expression is not stable during metastatic progression in a significant proportion of non-small-cell-lung cancer patients.

Epidermal growth factor receptor and KRAS mutation patterns is associated with non-small cell lung cancer patients

mutations in EGFR is associated with Non-Small-Cell lung Carcinoma

Frequent EGFR mutations is associated with brain metastases of lung adenocarcinoma

Patients with non-small cell lung cancer and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation

epidermal growth factor receptor has a role in response to gefitinib treatment in patients with non-small cell lung cancer

T790M mutation is sometimes present in a minor population of tumor cells during the development of non-small cell lung cancer.

The findings of EGFR abnormalities in lung cancer have supported the notion that different molecular mechanisms and pathways are involved in the pathogenesis of lung cancer arising in never and ever smokers.

activating mutations in the TKD domain of EGFR contribute to radiosensitivity of non-small-cell lung carcinoma

the impacts of smoking and sex on the risk of EGFRmut non-small-cell lung cancers (NSCLC) are different from those for EGFRwt NSCLC

Epidermal growth factor receptor mutations are associated with adenosquamous carcinoma of the lung

somatic alterations in p53 and EGFR have roles in progression of primary lung cancer

EGFR gene mutation does not change the effect of gefitinib in non-small cell lung cancer cells

EGFRvIII mutation in lung cancer is correlated with increased expression of EGFR

The number of dinucleotide repeats in this receptor identifies a possible susceptible population to lung cancer.

mutations in epidermal growth factor receptor is associated with lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas

Findings suggest that the EGFR mutation is frequent in Korean lung cancer patients.

Describe association between EGFR polymorphisms and geftinib treatment outcome and toxicity in non-small-cell lung cancer patients.

Potentially interesting value of the serum levels of sEGFR and EGF, especially when combined, as markers for non-small cell lung cancer and head and neck cancer.

mutations in the EGFR tyrosine kinase domain correlate with the clinical response to Gefitinib in lung cancer patients.

examinination of distributions of three polymorphisms and their relationships to each other and to EGFR gene mutations and allelic imbalance (AI) in non-small cell lung cancers

Frequencies of EGFR mutations were similar in both the alveolar and bronchial types of lung cancer

Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

results suggest the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway have already been identified. Our findings also implicate FGFR4 in the pathogenesis of a subset of lung adenocarcinomas

EGFR pathway, EGFR mutation and/or amplification, may be involved in lung carcinogenesis.

Frequent osteopontin expression is typical of, but not specific for malignant pleural mesothelioma, whereas it appears to select pulmonary adenocarcinoma cases with p65 and MMP-9 expression, suggesting a link with EGFR signalling pathways.

Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from male and female Japanese patients.

observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer

delE746-A750+L858R double activating EGFR mutations exist in Chinese non-small cell lung cancer patients and both locate on the same allele

Somatic mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene is associated with the sensitivity of non-smal cell lung cancer (NSCLC) to TK inhibitor Gefitinib.

It seems that continued EGFR tyrosine kinase inhibition may be beneficial to EGFR-mutant lung cancers.

study of EGFR, HER2, TP53& KRAS mutations of p14arf expression of non-small cell lung cancers in relation to smoking

EGFR and K-ras mutations may have a role in progression of resected non-small-cell lung cancer

In Chinese lung cancer patients, a low number of CA repeats in intron 1 of the EGF receptor gene is associated with a better clinical outcome during therapy with gefitinib.

Increased expression of erbB3 may play an additional role in non-small-cell lung carcinomas especially in female, nonsmoker, adenocarcinoma, and with EGFR gene mutation.

EGFR insertion mutation in exon 20 could not be ignored from Japanese lung cancers

study found that EGFR down-regulation was impaired in two non-small cell lung cancers with EGFR tyrosine kinase domain mutations; the mutant receptors were poorly ubiquitylated and exhibited decreased association with the ubiquitin ligase Cbl

EGFR immunoreactivity with basal cytoplasmic pattern was exclusively seen in terminal respiratory unit type lung adenocarcinoma and a subset of these cases was seen with EGFR mutations in the responders to EGFR inhibitor therapy

Regarding EGFR, no specific mutation was detected in five of the six patients with lung cancer whereas one female patient who had never smoked had a missense mutation.

EGFR mutations appear to occur in highly selected subgroups of lung cancer patients: adenocarcinomas with bronchiolo-alveolar carcinoma components and patients of the female gender.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations is associated with non small cell lung cancers

EGFR mutations do not have significant prognostic value in primary resected non-small cell lung cancer

CCND1/GAPDH mRNA levels were significantly higher in lung cancer with EGFR mutation than in lung cancer without EGFR mutation

EGFR gene amplification or protein expression is not a predictor of gefitinib efficacy in Japanese patients with non-small-cell lung cancer

The serum CEA level appears to be closely associated with the presence of EGFR gene mutations in patients with pulmonary adenocarcinomas.

Wnt and epidermal growth factor receptor signaling pathways are altered through aberrant methylation and mutation in non small cell lung cancer

These results suggest that the EGFR polymorphisms, particularly the 181945C>T polymorphism, could be used as markers for the genetic susceptibility to lung cancer.

Phosphorylated-GSK3beta-ser9 and EGFR are involved in the histogenesis of different lung carcinomas.

EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

EGFR mutations were frequently found in lung adenocarcinoma with ground-glass opacity (GGO) on High-Resolution CT in this study.

MET amplification occurs independently of EGFR(T790M) mutations in lung adenocarcinoma

Overexpression of EGFR in lung adenocarcinomas with components of BAC histology correlate with never-smoker status and improved overall survival and disease-free interval.

EGFR mutations and the administration of EGFR tyrosine kinase inhibitors during Whole-brain radiation therapy (WBRT) were independent predictors of response to WBRT in brain metastases of lung adenocarcinoma.

EGFR mutations in carcinogenesis of lung adenocarcinoma: distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma

mutations of EGFR and K-ras genes represent an early event in lung adenocarcinomagenesis, and AAH convincingly seems to be a precursor lesion in a subset of cases of adenocarcinoma.

study found that EGFR high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by immunohistochemistry

cases of primary lung carcinoma were analyzed for correlations between the presence of somatic mutations of the epidermal growth factor receptor (EGFR) gene and the phosphorylation status of EGFR.

Data suggest that Fra-1 enhances lung cancer epithelial cell motility and invasion by inducing the activity of matrix metalloproteinases, in particular MMP-2 and MMP-9, and EGFR-activated signaling.

first direct comparison of survival of resected patients with either EGFR or KRAS mutant lung adenocarcinomas compared with those wild type for both genes; EGFR & KRAS mutations define distinct molecular subsets of resected lung adenocarcinoma

EGFR mutations are frequently found in female, nonsmoker patients with adenocarcinoma suggests that some genetic predisposition causes the mutations in the EGFR gene, which result in carcinogenesis and maintenance of lung cancer.

siRNA-mediated knockdown is effective in lung adenocarcinomas with EGFR mutation and those with resistance to gefitinib by acquired mutation in EGFR.

Epidermal growth factor receptor mutation might be a very early event in the pathogenesis of adenocarcinoma of the lung.

In stage III non-small cell lung cancer, there was a significant association between TTF-1 and EGFR

allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers

EGFR and KRAS mutations occur early during the multistage pathogenesis of peripheral lung adenocarcinomas

Gene amplification of EGFR was found in 11 lung cancers. Nine of the cancers showed heterogeneous distribution, and amplification was associated with higher histologic grade or invasive growth.

Our data suggest that EGFR mutations are associated with papillary adenocarcinoma lung cancer

study reports on the associations of EGFR mutation, amplification, and protein expression in non-small cell lung cancer

non-small cell lung cancer patients with exon 19 deletions survived longer following gefitinib treatment than those with exon 21 point mutations

Exon 19 of EGFR mutation and CA-repeat polymorphism in intron 1 is associated with lung cancer

Epidermal growth factor receptor mutations are associated with non-small-cell lung cancers

Some lung adenocarcinomas may demonstrate intratumoral heterogeneity for the occurance of EGFR mutation.

EGFR gene mutations are frequently seen in lung adenocarcinomas with bronchioloalveolar differentiation and can be linked to chromosomal imbalances and increased VEGF expression

mutations in the epidermal growth factor receptor correlate with increased response in patients with non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors

Novel EGFR mutation D1012H and polymorphism at exon 25 is associated with lung cancer.

epidermal growth factor receptor gene mutations may have roles in malignant pleural effusion of lung adenocarcinoma

there is a role of the EGFR gene, now as a target of miRNA regulation in lung cancer

EGFR-tyrosine kinase polymorphism might be associated with clinicopathological background of lung cancers.

There were multi-nucleotide in-frame deletion mutations in exon 19 of EGFR gene. mutations of the exon 19 of EGFR gene were higher in female, non-smoking and adenocarcinoma lung cancer patients.

EGFR gene mutation was the only significant molecular predictor for time-to-progression in non small cell lung cancer.

Somatic mutations in the exons 18 to 21 of the tyrosine kinase (TK) domain of EGFR are correlated with a high likelihood of response to EGFR TK inhibitors in advanced lung cancer.

Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status.

selected polymorphic variants in the estrogen biosynthesis and metabolism pathways are unlikely to be major genetic modifiers of the prevalence of EGFR-mutant non-small-cell lung cancer

the mutational spectrum of somatic mutations of EGFR in non-small cell lung cancer (Analytical database)

analysis of EGFR mutations in small samples obtained from patients with non-small cell lung cancer

CSF1, EGFR, and CA IX have roles in increasing survival in early-stage squamous cell carcinoma of the lung

the length of the EGFR CA repeat polymorphism in lung carcinoma is inversely related with level of EGFR protein expression in the carcinoma

ADAM8 and EGFR are overexpressed in non-small cell lung cancer.

addiction (dependence on a single oncogene) to the mutationally activated EGFR in human lung cancer cells

An amino acid substitution in EGFR polymorphism may be associated with favorable prognosis of advanced lung cancers.

EGFR mutations indicates that they are related to the mechanism of the pathogenesis of lung cancer.

multiple mechanisms underlie acquired gefitinib resistance, and selection on a background of EGFR genetic heterogeneity also contributes to acquisition of resistance in a proportion of nonsmall cell lung cancers

The combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival in non-small-cell lung cancer treated with gefitinib.

EGFR mutations significantly predict both a survival benefit from gefitinib and a favorable prognosis in patients with advanced lung adenocarcinoma

The median survival time of patients with the EGFR somatic mutation was significantly longer in patients with advanced non-squamous, non-small cell lung cancer

EGFR mutations are associated with non-small cell lung cancer.

Epidermal growth factor receptor intron-1 polymorphism is associated with gefitinib response in advanced non-small cell lung cancer.

mutations in epidermal growth factor receptor is associated with non-small cell lung cancer.

analysis of epidermal growth factor receptor mutations in small cell lung cancer

EGFR mutations are associated with non-small cell lung cancer.

EGFR mutations may be a valuable prognostic factor for disease free survival of surgically treated lung adenocarcinoma patients independently from adjuvant chemotherapy

mutations in exons 19 or 21 are considered to be a good predictor of the efficacy of gefitinib therapy for non-small cell lung cancer

EGFR mutations not only increase receptor activity, but also alter responses of downstream signaling cascades in human non-small cell lung cancer cell lines.

Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively, relative to spontaneous doublets in mouse (6% and 2.3% versus 0.7%).

genetic polymorphism is associated with a significantly increased risk of female lung adenocarcinoma

high gene copy number might be associated with shorter survival in patients with non-small-cell lung cancer in Japan

epidermal growth factor receptor-mutation has a positive non-small cell lung cancer response to Erlotinib combined with cyclosporine in a liver-transplant recipient.

Germ-line and somatic mutations of the EGFR T790M is associated with lung cancer.

Epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.

analysis of distinct EGFR mutations in non-small cell lung cancer

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

associated with non-small lung cancer

Patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations show response to gefitinib.

Phosphorylated EGFR appears to be a better indicator for lower disease-free survival than EGFR overexpression itself in localized non-small cell lung cancer.

T790M-EGFR mutation is associated with relapses in lung cancer.

Substantial discordance in EGFR and K-RAS mutational status between the primary tumours and corresponding metastases in patients with non-small-cell lung cancer.

EGFR gene gain does not impact survival after resection in non-small-cell lung cancer.

Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.

In patients with non-small cell lung cancer, there is a higher frequency of epithelial markers in patients with EGFR mutation.

The EGFR-mutated lung adenocarcinoma showed a significantly higher prevalence of past illness involving the gastric cancer in males or uterine myoma in females

EGFR mutations is associated with non-small-cell lung cancer.

K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience.

EGFR/KRAS mutation testing of multiple lung adenocarcinomas can assist in differentiating multiple primary lung adenocarcinomas from metastatic lesions.

EGFR T790M mutation and c-MET amplification can occur in tyrosine kinase inhibitor-resistant non-small cell lung cancer with wild-type EGFR. These genetic defects might be related to different survival outcome.

EGFR mutation is associated with metastatic in non-small cell lung cancer.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

examined the effect of EGFR mutations and BRCA1 mRNA levels on outcome in advanced non-small-cell lung cancer

Activating mutations within the EGFR TK domain can be used to predict the risk of recurrence in curatively resected pulmonary adenocarcinoma.

Results show that DUSP4 is involved in negative feedback control of EGFR signaling, and provide functional validation for its role as a growth suppressor in EGFR-mutant lung adenocarcinoma.

Gefitinib monotherapy confers substantial clinical benefit in terms of progression-free survival and overall survival in non-small cell lung cancer patients with EGFR mutations.

These results suggest that aberrantly increased expression of miR-21, which is enhanced further by the activated EGFR signaling pathway, plays a significant role in lung carcinogenesis in never-smokers, as well as in smokers.

the smoking dose predicted EGFR mutations with a moderate diagnostic accuracy in patients with non-small-cell lung cancer.

EGFR protein overexpression and increased EGFR gene copy number is associated with sarcomatoid carcinomas of the lung.

Downregulation of EGFR is associated with non-small cell lung cancer metastasis.

examination of lung cancer samples revealed a significant correlation of miR-125a-5p repression with lung carcinogenesis

Estrogen receptor alpha and beta expression distinguishes a subset of NSCLC that has defined clinicopathologic and genetic features. In lung adenocarcinoma, estrogen receptor alpha expression correlates with EGFR mutations.

Epidermal growth factor receptor mutations were more frequently observed in females, in non-smokers, and in the presence of bronchioloalveolar features in 411 lung adenocarcinomas .

EGFR and KRAS status of primary lung carcinomas may not predict the status in the corresponding metastases.

The c.2235-2249 (pGlu746-Ala750del) mutation in exon 19 was found in 2 patients with lung adenocarcinoma. 26% of the NSCLC cases overexpression EGFR had reduced PTEN and increased Mcl-1 expression.

African American patients with non-small-cell lung cancer are significantly less likely than white counterparts to harbor activating mutations of EGFR.

Using lung adenocarcinoma samples and cell lines derived from lung adenocarcinomas, we demonstrated that the gene copy number for MET in lung adenocarcinoma tissue samples was increased over EGFR, HGF, and PXN and that it correlated with better prognosis

EGFR amplification and exon 19 deletion mutations are associated with lung adenocarcinomas.

Aberrant methylation and alterations of EGFR signaling is associated with chronic obstructive pulmonary disease-related non-small cell lung cancer.

EGFR and KRAS mutations were found in 33 (10%) and 78 (23%) of lung adenocarcinomas, respectively, whereas 226 (67%) cases were negative for both mutations

EGFR mutations are associated with lung adenocarcinomas.

Notch3 not only has a crucial role in lung cancer through regulating apoptosis, but also cooperates with the EGFR-MAPK pathway in modulating Bim.

EGFR mutational status was associated with clinical response in non-small cell lung cancer.

Discovery of EGFR, the EGFR signal transduction pathway and mutations of the EGFR gene in lung cancers and glioblastomas. Review.

epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer is associated with dramatic response to low-dose erlotinib.

Molecular studies showed 3 (20%) of 15 oncocytic adenocarcinomas of lung with EGFR mutations and 3 additional cases with KRAS mutations.

Matrix-assisted laser desorption ionization remains a potent and highly clinically significant predictor of survival after first-line treatment with erlotinib in non-small-cell lung cancer patients with wild-type EGFR mutation.

EGFR mutation combined with HER2/3 expression is a significant predictor for gefitinib efficacy on Chinese patients with advanced non-small cell lung cancer.

simultaneous detection of p53, Rb, p16, and EGFR in a suspension microarray facilitates rapid diagnosis of lung cancer

No specific computed tomography appearance, which would correlate with either an EGFR mutation or a KRAS mutation was associated with adenocarcinoma of the lung with bronchioloalveolar features.

EGFR mutation was recognized in approximately 20% of patients with pulmonary pleomorphic carcinoma.

Features of KRAS mutations in lung cancer and contrast these with the features of EGFR mutations.

EGFR mutations did not correlate with pAkt and pERK expression in lung adenocarcinoma.

Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer.

Overview of the current understanding of the lung adenocarcinoma subset harboring EGFR mutations with special reference to the molecular classification of lung cancer and the novel concept of the "terminal respiratory unit."

mutations in EGFR is associated with lung adenocarcinoma.

EGFR -191C/A, -216G/T, and R497K polymorphisms are associated with diarrhea when using gefitinib in non small cell lung cancer patients.

mutations in the epidermal growth factor receptor gene is associated with response to treatment with EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer.

Non-small cell lung cancer harboring sensitizing EGFR mutations are associated with osteoblastic responses during disease control by tyrosine kinase inhibitor treatment.

the gene expression profiles of lung adenocarcinoma are linked to histopathological grading and survival but not to EGF-R status

The results demonstrated the presence of intratumor molecular heterogeneity for the clinically relevant EGFR mutated alleles in these early-stage lung tumors

EGF receptor tyrosine phosphorylation in lung cancer cells is regulated by Neuromedin B receptors.

These results indicate that imbalance alterations at several chromosomal regions occur significantly more frequently in lung adenocarcinomas with EGFR mutations than in those without such mutations.

Results showed a comparable rate of EGFR kinase domain mutations in lung adenocarcinomas from Chinese male and female never-smokers.

Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2 receptors demonstrated antiangiogenic/antitumor effects in a lung cancer model.

EGFR sequence analysis was the only method useful for predicting response and progression-free survival following tyrosine kinase inhibitor therapy in non-small cell lung carcinoma.

mutation in EGFR is associated with Neratinib response in non-small-cell lung cancer.

mutations may predict the biological nature of pulmonary adenocarcinomas and facilitate new therapies.

Epidermal growth factor receptor mutation is associated with early stage of pulmonary adenocarcinoma development and tumor initiation from the preneoplastic lung parenchyma to neoplastic conditions.

EGFR mutations are associated with erlotinib at a dose of 25 mg daily for non-small cell lung cancers.

Somatic epidermal growth factor gene point mutation is associated with Good clinical response to gefitinib in non-small cell lung cancer.

EGFR mutations are associated with HLA-A2 in female patients with adenocarcinoma of the lung.

EGFR mutations are associated with lung adenocarcinomas.

EGFR gene mutations are not associated with non-small cell lung cancer.

analysis of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors

In nonsmall cell lung cancer patients with brain metastases, EGFR mutation status is associated with improved survival

EGFR mutation is associated with high chemotherapy response rate of non-small cell lung cancer.

Overexpressions of nuclear EGFR is associated with non-small cell lung cancer.

High EGFR expression, copy number and mutation is associated with lung adenocarcinomas.

2 cases of pulmonary adenocarcinoma with unique microcystic growth pattern; Q787Q polymorphism was found in microcystic component but not in papillary component; findings illustrate intratumoral heterogeneity of EGFR gene polymorphism

EGFR gene mutations are associated with lung adenocarcinomas with features of the non-mucinous subtype of bronchioloalveolar carcinoma.

Overexpression of EGFR and COX-2 may play an important role in the tumorgenesis, progression and malignancy of lung cancer. Detection of EGFR and COX-2 expression might be helpful to diagnosis and prognosis of lung cancer.

Activating epidermal growth factor receptor mutations are associated with response to gefitinib in non-small cell lung cancer.

Epidermal growth factor receptor mutations are associated with better response to therapy in non-small cell lung cancer.

complex EGFR mutations is associated with different efficacy to gefitinib in non-small cell lung cancer.

Epidermal growth factor receptor mutation is associated with lung cancer.

EGFR gene mutation is associated with non-small cell lung cancer.

mutations in EGFR is associated with adenocarcinoma of the lung.

When patients with lung adenocarcinomas who had EGFR mutations developed pulmonary metastases, they tended to be diffuse and random, including military metastases.

more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR

Report on the clinical utility of reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutatations.

cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer.

Gefitinib and Erlotinib induce responses in over 70% of non-small cell lung carcinoma patients harboring EGFR mutations, with progression-free survival.

non-small cell lung cancer specimens harboring EGFR activating mutations are more likely to express low ERCC1 mRNA levels.

Overexpression of EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

EGFR mutations are associated with drug sensitivity in non-small-cell lung cancer.

Constitutive activation of EGFR/Akt/mTOR pathway was present in defined subset of nonsmall cell lung carcinomas.

EGFR gene mutations were frequently observed in not only non-small-cell lung cancer (NSCLC), but also in ovarian cancer in Japanese patients.

The EGFR T790M mutation is the main molecular mechanisms responsible for acquired resistance to gefitinib or erlotinib in patients with non-small cell lung cancer harboring a mutation in the EGFR gene.

EGFR mutations in exon 19 and exon 21 in non-small cell lung cancer patients may relate to the tumor sites

Phosphorylation sites related to activating mutations in EGFR as well as sensitivity to erlotinib were identified using 31 lung cancer cell lines.

Exon 19/21 mutations and high EGFR copy is associated with response to adjuvant chemotherapy in non-small cell lung cancer.

The frequency of EGFR mutation in Chinese non-small cell lung cancer patients is higher than that in Westerners, but the frequency of K-ras mutation is quite opposite.

analysis of resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer

lung adenocarcinomas harboring mutations in EGFR exon 19 or 21 are associated with improved treatment response.

age at the time of diagnosis in female patients with non-small cell lung cancer may be associated with the frequency of EGFR mutations.

The overexpressions of VEGF-C and EGFR genes are closely related to lymph node metastasis. VEGF-C mRNA and EGFR mRNA are valuable biomarkers for early diagnosis, clinical prediction and prognosis for lung cancer.

EGFR-mutated lung cancer: a paradigm of molecular oncology.

Case Report: EGFR V843I mutation confers predisposition to lung adenocarcinoma and tyrosine kinase inhibitor resistance.

Epidermal growth factor receptor mutations are associated with small cell lung cancer.

epidermal growth factor receptor exon 19 deletion is associated with Miliary never-smoking adenocarcinoma of the lung.

In a group of clinically selected patients, EGFR and KRAS analysis was able to define distinct molecular subsets of lung adenocarcinoma.

pulmonary adenocarcinoma specimens were prepared for staining by two antibodies that recognise products of in-frame deletions in exon 19 (E746_A750del) and a point mutation at codon 858 in exon 21 (L858R) of the EGFR gene.

There is a positive correlation between the EGFR and c-Met protein expression and the differentiation of non-small cell lung cancer.

Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs

Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations are associated with non-small cell lung cancer patients

Data show distinct significant correlations between TITF-1 protein expression and DNA copy gain with mutations in the lung adenocarcinoma-prevalent EGFR and KRAS oncogenes.

EGFR mutations are associated with drug resistance in non-small cell lung cancer.

Data show that the L858R mutation of EGFR is associated with SNP of estrogen biosynthesis and metabolism genes CYP17, CYP19A1, ERalpha, and COMT in never-smoking female lung adenocarcinoma patients.

high prevalence of EGFR mutations in non-smal cell lung cancer patients in India

EGFR mutation is associated with response to therpay in non-small cell lung cancer.

A859T EGFR mutation is associated with lung cancer.

Epidermal growth factor receptor gene mutations is associated with squamous cell lung carcinoma.

EGFR and c-Met may interact in a synergistic manner in the oncogenesis and development of non-small cell lung cancer. expressions were higher in smokers than in nonsmokers.

COX-2 and EGFR are overexpressed in non-small cell lung cancer.

EGFR mutations were associated with pulmonary pleomorphic carcinoma.

Results suggest that EGFR mutation is not a prognostic marker in Korean patients with advanced lung adenocarcinoma who had not been treated with EGFR tyrosine kinase inhibitors.

lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations.

data identify NF-kappaB as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provide insight into the mechanisms by which tumour cells escape from oncogene dependence

genetic polymorphism is assopciated with recurrent non-small-cell lung cancer in patients receiving gefitinib

results show beta1-integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.

A direct association between EGFR mutations and ER beta expression in lung cancer cell lines is lacking.

EGFR mutations and amplifications in 23 adenosquamous carcinomas of lung

Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma.

EGFR mutation is an early event in the pathogenesis of lung adenocarcinoma and may facilitate the tumor into aggressive behavior

EGFR mutations in exons 19 (deletion mutation) and 21 (L858R mutation) predict a longer progression-free survival in patients with advanced non-small cell lung cancer.

in non-small cell lung cancer (NSCLC), EGFR mutation was independently associated with the female gender, negative expression of progesterone receptor, and negative expression of aromatase

Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells

Data show that IL-8 overexpression is induced by activating mutations of KRAS or EGFR in non-small cell lung cancer (NSCLC) cells.

EGFR gain is associated with poor overall survival for lung adenocarcinoma patients and may be used as prognostic marker

Higher dosage of the epidermal growth factor receptor mutant allele is associated with lung adenocarcinoma.

the incidence of EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung (ADSQ) were similar to those of Asian patients with adenocarcinoma; EGFR silent mutations accounted for a large proportion in ADSQ

mutations in EGFR is associated with drug resistance and epithelial to mesenchymal transition in lung cancer.

The pulmonary Pathology Working Group of the Austrian Society of Pathology, after intense discussions and in consensus with Oncologists and Pulmonologists, recommends a priori EGFR mutation analysis for all cases of adenocarcinoma.

In patients with surgically resected lung adenocarcinomas, KRAS and EGFR gene mutation status of tumors was not associated with disease-free survival. EGFR gene mutations were linked to favorable overall survival and median survival time after recurrence.

epithelial growth factor receptor mutations in cerebrospinal fluid is associated with lung adenocarcinoma suspected of neoplastic meningitis.

Propose a Systems Biology approach to understand the molecular biology of EGFR and IGF1R pathways in non-small cell lung cancer.

EGFR gene alterations are associated with lung cancer.

data indicate that EGFR T790M exists in pretreatment non-small cell lung cancer at low levels irrespective of histologic types

the expression and clinical relevance of c-Cbl, Cbl-b and EGFR in non-small cell lung cancer

EGFR mutations were discordant between the primary tumor and the corresponding metastases in non-small cell lung cancer

Epidermal growth factor receptor mutation is associated with treatment response in non-small cell lung cancer.

EGFR mutations are associated with docetaxel response in lung cancer.

An evaluation of cytomorphologic features of advanced lung adenocarcinomas that might be associated with EGFR mutational status.

EGFR and MET coordinate to drive non-small cell lung carcinoma tumorigenesis.

Increasing sialylation and fucosylation could attenuate EGFR-mediated invasion of lung cancer cells. However, incorporation of the core fucose by alpha1,6-fucosylatransferase (FUT8) would promote EGFR dimerization and phosphorylation.

EGFR mutation is associated with nonsmall cell lung cancer.

analysis of epidermal growth factor receptor (EGFR) in lung cancer

EGFR mutations are associated with response to therapy in lung adenocarcinoma.

Low baseline sEGFR is associated with reduced survival in advanced non-small-cell lung cancer

EGFR mutations were discordant between primary tumors and corresponding metastases in a significant portion of lung adenocarcinomas.

Results suggest that the heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

the structural, molecular, and clinical implications of EGFR exon 20 insertions in non-small-cell lung cancer (Review)

This nomogram could be highly useful to predict the presence of EGFR mutations in lung adenocarcinoma in non-Asian patients when mutational profiling is not available or possible.

EGFR-activating mutations are associated with treatment responses of lung adenocarcinoma .

Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression in association with EGFR gene mutation.

EGFR mutations are associated with the response to therapy in non-small cell lung cancer.

EGFR mutation is associated with erlotinib accumulation in brain metastases from non-small cell lung cancer.

EGFR mutant in non-small cell lung cancer is not associated with erlotinib resistance for Central Nervous System metastases.

EGFR mutations are associated with treatment response in lung cancer.

EGFR-activating mutations are associated with treatment response in non-small cell lung cancer.

Adenocarcinoma is the most frequent EGFR mutation pathologic type in lung cancer.

EGFR immunohistochemistry is not a suitable criterion for reliably selecting patients for anti-EGFR treatment. EGFR in situ hybridization may be reliably performed with high accuracy, allowing treatment decisions for lung cancer.

EGFR mutations are associated with non-small cell lung cancer.

Epidermal growth factor receptor gene mutations are associated with treatment response in advanced non-small cell lung cancer

Concurrent exon 19 EGFR mutation and ALK rearrangement is associated with response to erlotinib in lung adenocarcinoma.

The epidermal growth factor receptor (EGFR) is over-expressed in 40-80% of patients with non-small-cell lung cancer (NSCLC).

There was no significant difference in EGFR mutation frequency between the primary and metastatic nonsmall cell lung tumors.

Review: tumour-associated activating mutations in EGFR can identify patients with non-small-cell lung cancer who are likely to have a good response to tyrosine kinase inhibitors.

High EGFR expression is a tumour biomarker that can predict survival benefit from the addition of cetuximab to first-line chemotherapy in patients with advanced non-small lung cancer.

Persistent activation of signaling by the AKT-survivin pathway induced by PTEN loss underlies a mechanism of resistance to erlotinib-induced apoptosis in EGFR mutation-positive non-small cell lung cancer.

FISH-positive EGFR expression is associated with gender and smoking status, but not correlated with the expression of ERCC1 and BRCA1 proteins in non-small cell lung cancer.

2 of 40 small-cell lung cancer cases had mutations in EGFR exon 19: a female non-smoker with SCLC & adenocarcinoma, and a male smoker with SCLC & squamous cell carcinoma.

Protein expression of VEGF, EGFR and MMP-9 is elevated in non-small cell lung carcinomas, correlating with progression.

Small cell lung cancer with an epidermal growth factor receptor mutation is associated with primary gefitinib-resistant adenocarcinoma of the lung

Studies indicate that tumor heterogeneity and probably also previous systemic treatment may be an obstacle for correct interpretation of EGFR status in non-small cell lung cancer (NSCLC).

The EGFR mutation rate in pleural metastatic tissues of lung adenocarcinoma acquired through video-assisted thoracoscopic surgery was higher compared to that in surgical resection specimens.

Data indicate that PIK3CA mutations occur in lung adenocarcinomas, usually concurrently with EGFR, KRAS, and anaplastic lymphoma kinase (ALK).

EGFR mutation status is associated with lung adenocarcinoma.

Report validity EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.

EGFR mutation is associated with response to therapy in non-small-cell lung cancer.

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.

EGFR mutations, especially exon 19 deletions are associated with pulmonary tuberculosis in patients with adenocarcinoma of the lungs.

the existence of sEGFR isoforms specifically produced by NSCLC tumor cells which could represent a new potential biomarker for diagnosis and therapy of lung tumors.

study has shown that EGFR exon 19 insertions are a new family of sensitizing EGFR mutations in lung adenocarcinoma

HER2 seems to be a valid therapeutic target of EGFR inhibitors in HER2-addicted lung carcinomas

EGFR and K-ras mutations frequently occur randomly in multifocal lung adenocarcinomas

L858R/T790M mutant epidermal growth factor receptor is associated with lung cancer.

Our findings suggest that EGFR/KRAS mutations do not occur in pure pulmonary squamous cell carcinoma (SQCC).

EGFR216, EGFR191, ABCG2, and AKT1 polymorphism is not associated with erlotinib response in non-small cell lung cancer.

High incidence of EGFR mutations is associated with smoking and lung adenocarcinoma histology

suggest that mutations of EGFR good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value

in patients with nonsmall cell lung cancer, ALK gene rearrangement was significantly associated with pericardial disease and pleural disease; patients with ALK gene rearrangements and patients with EGFR mutations were predisposed to liver metastasis compared to triple negative cohort

Dephosphorylation of AKT in association with EGFR mutation is a candidate marker for sensitivity to cetuximab in lung cancer.

The incidence of EGFR mutations in non-small cell lung cancer is higher in Chinese patients, especially in non-smoking female patients with adenocarcinoma.

In patients with non-small cell lung cancers, EGFR gene mutation rates in males were significantly higher than in females, and higher in non-smokers than in smokers.

EGFR gene mutations occur more frequently in females, non-smokers and patients with adenocarcinoma. The presence of EGFR amplification appears unrelated to age, gender, histopathological types of lung cancer and subtypes of adenocarcinoma.

EGFR mutations occur frequently in females, non-smokers and adenocarcinomas, bronchioloalveolar carcinomas, and adenosquamous carcinomas in patients with non-small cell lung cancer. The patients with EGFR mutations have better prognoses.

The expression of EGFR was associated with differentiation, clinical stage, and lymph node metastasis, but was not associated with gender, age and histological types of lung cancer.

non small cell lung cancer brain metastases harboring the exon 19 deletion mutation in the EGFR were smaller, more numerous and less edematous

EGFR gene mutation and gene high copy number are more common in Chinese non-small cell lung cancer patients with adenocarcinomas, advanced stage, non-smokers and females.

Suggest that the enhanced S1P3-EGFR signaling axis may contribute to the tumorigenesis or progression of lung adenocarcinomas.

EGFR mutations is associated with response to therapy with advanced non-small-cell lung cancer.

these findings suggest that miR-542-5p may act as an important modulator of EGFR-mediated oncogenesis, with potential applications as a novel therapeutic target in lung cancer.

Data suggest that pulmonary metastasis is corrected with levels of Geminin, cleaved caspase-3, CD44, E-cadherin, epidermal growth factor receptor, and CD204 in cancer cells within permeated lymphatic vessels.

EGFR exon 19, 20 and 21 mutations were higher in females compared to males and higher in adenocarcinomas compared to other forms of lung cancers

Studies indicate that EGFR signaling in EGFR-mutant lung cancer and hepatocyte growth factor (HGF) ligand-triggered bypass signals (HGF-Met and EGFR ligands-EGFR) must be simultaneously blocked to avoid the resistance.

Results identify a link between the p14(ARF) and EGFR pathways and suggest that EGFR L858R counteracts the pro-apoptotic function of p14(ARF) by downregulating its expression to promote carcinogenesis in the lung.

The EGFR gene was highly mutated and mainly L858R substitutions occurred as well as insertions and deletions in lung adenocarcinomas from a Chiba Prefecture, Japan cohort.

This study showed an association between vascular-poor area of primary lung adenocarcinomas and EGFR status

lung cancer patients with EGFR-mutations had longer PFS with taxane than gemcitabine when receiving a platinum-based doublet regimen.

Results suggest that EGFR mutations are common in female, never-smoking lung cancer cases from the United States, and EGFR mutations are unlikely due to exposure to radon or passive smoking.

an EGFR mutation may have a role in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis

RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations.

Results indicate that epidermal growth factor receptor (EGFR) L861Q mutation is a frequent EGFR mutation in pulmonary mucoepidermoid carcinoma (PMEC).

The aim of the present study was to determine the frequency of EGFR and KRAS mutations in non-small cell lung cancer in the West European Dutch population.

nonsmall cell lung cancers (NSCLC) harboring activating EGFR mutations were more likely to express low ERCC1 and thymidylate synthetase (TS) mRNA levels; patients with NSCLC who had ALK rearrangement were more likely to express low TS mRNA levels

Gene amplification is related with EGFR gene mutation in Chinese patients with non-small cell lung cancer.

The in-frame deletion in EGFR exon 19 is associated with polymorphisms in DNA repair and detoxification metabolism genes in never-smoking lung adenocarcinoma patients.

Plasma EGFR mutations are associated with non-small cell lung cancer.

EGFR mutation is associated with response to treatment in adenocarcinoma of the lung.

70 % of pulmonary adenocarcinoma female non-smoker Asian patients harbor EGFR mutations.

Epidermal growth factor receptor nonsense mutations are associated with clinical response in non-small-cell lung cancer.

Aim of this study was to characterize further the expression of RUNX3 in lung cancers.Inactivation of RUNX3 was observed in 70% of the adenocarcinoma samples, and this was associated with promoter hypermethylation but not biased to EGFR/KRAS mutations.

TIP30 functions as a tumor suppressor to inhibit EGFR cytoplasmic and nuclear signaling and suppress adenocarcinogenesis in the lung.

increased activation of AXL and evidence for epithelial-to-mesenchymal transition in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation

EGFR mutation rate in Korean patients with non-adenocarcinoma of the lung is relatively high and that the clinical outcomes of EGFR TKIs are modest.

lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Presence of membrane-bound ERalpha expression together with EGFR mutation was found to be an independent prognostic factor for survival in patients with lung adenocarcinoma, suggesting cross-talk between membrane-bound ERalpha and EGFR mutation

In patients with lung adenocarcinoma EGFR mutations were associated with longer overall survival.

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells

Chemotherapy may reduce EGFR mutation frequency in patients with non-small cell lung carcinoma, likely the result of a preferential response of subclones with EGFR mutations in tumors with heterogeneous tumor cell populations.

The aim of this study was to elucidate the correlation between the expression of cancer/testis antigens and clinicopathological factors, including the EGFR mutation, and to analyse the prognosis in lung adenocarcinoma.

Standard cytology provides adequate material for the assessment of EGFR and Kras mutational status in non-small cell lung cancer and colorectal cancer patients.

EGFR exon mutation is associated with non-small-cell lung cancer.

EGFR mutation is associated with response to therapy in lung cancer.

Authors suggest EGFR mutations are seen in greater frequency in mucoepidermoid carcinoma(MEC)in Asian populations, and that in these populations, EGFR mutations are seen in pulmonary but not in salivary MEC.

EGFR mutation was a predictor for advanced squamous cell lung cancer susceptibility to EGFR tyrosine kinase inhibitors.

EGFR mutation is associated with response to therapy in non-small-cell lung cancer.

EGFR Exon 20 mutations are associated with response to therapy in non-small-cell lung cancer.

EGFR T790M mutation is associated with response to therapy in lung cancer.

data indicate that SCD activity may control lung cancer cell metabolism, proliferation and survival by modulating the EGFR-->Akt/ERK signaling platforms

EGFR mutations are associated with HPV presence in Japanese patients with lung cancer.

EGFR mutation is associated with response to therapy in non-small-cell lung cancer.

EGFR mutation is associated with response to therapy in non-small-cell lung cancer.

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation is associated with non-small-cell lung cancer.

In lung cancer, EGFR mutation occurs cumulatively by unidentified internal/external factors other than smoking.

EGFR mutation is associated with response to therapy in lung cancer.

high concentration of gefitinib is not necessary to achieve long-term therapeutic effects in patients with lung adenocarcinoma harboring the EGFR mutation

EGFR mutation is associated with response to therapy in brain metastases of non-small cell lung carcinoma.

Case Report: molecular modeling of activating insertion mutation of EGFR gene in non-small cell lung cancer.

EGFR mutations are associated with radiotherapy response in non-small cell lung cancer patients with brain metastases.

Patient with EGFR-mutated lung adenocarcinoma benefited with high dose pemetrexed and gefitinib chemotherapy.

EGFR mutation is associated with response to therapy in lung cancer.

EGFR mutation is associated with metastasis in non-small-cell lung cancer.

EGFR mutation is associated with response to therapy in non-small-cell lung cancer.

Exon 19 EGFR mutation is associated with small-cell lung cancer with adenocarcinoma.

EGFR status can be determined in non-small cell lung cancer using silver-enhanced in situ hybridization.

3 lung adenocarcinoma patients with early venous thromboembolisms had activating mutations in EGFR, suggesting such mutations may increase thromboembolic risk.

EGFR gene mutation is associated with response to therapy in lung cancer

EGFR mutation is associated with responsiveness to therapy in lung adenocarcinomas.

we suggest that CM1 could be developed as a therapeutic target of lung cancer regardless of EGFR mutation status.

EGF receptor single nucleotide polymorphisms have a cumulative effect on decreasing lung adenocarcinoma risk in never-smoking women with hormone replacemtn therapy use.

collegiate smokers (former smokers who smoked between 101 lifetime cigarettes and 5 pack-years)with advanced-stage lung cancers represent a distinct subgroup of patients with a higher frequency of KRAS mutations and lower frequency of EGFR mutations compared with never smokers

Data indicate that the PTEN loss and activation of AKT signaling pathway contributed to erlotinib resistance in EGFR-mutant non-small cell lung cancer (NSCLC) cell line H1650.

mutation is associated with more frequent distant relapses of non-small cell lung cancer

Vandetanib might be effective in non small cell lung carcinoma with EGFR mutations that lack PTEN expression.

mutations in epidermal growth factor receptor gene is associated with response to therapy in non-small-cell lung cancer.

Epidermal growth factor receptor mutation is associated with response to therapy in resected advanced non-small-cell lung cancer.

The present study revealed that the EGFR mutation rate in Bangladeshi patients with adenocarcinoma of the lung was higher than in African-American, Arabian, and white Caucasian patients, and was lower than in East Asia

Prognosis is worse in non-small cell lung cancer patients with KRAS mutation than that with wild type.

Derlin-1 is overexpressed in non-small cell lung cancer and promotes invasion by EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.

The status of EGFR and KRAS mutation in serum was not prognostic in patients with advanced non-small cell lung cancer

Epidermal growth factor receptor mutation is associated with response to therapy in advanced non-small-cell lung cancer.

EGFR single nucleotide polymorphisms are associated with response to therapy in non-small-cell lung cancer.

EGFR exon 20 insertions is associated with non-small-cell lung cancer.

our data suggest that the dual inhibition of FAK and EGFR by using plasmid vector-based RNA interference might be a novel therapeutic approach to the treatment of human non-small-cell lung cancer .

EGFR and KRAS mutational rates were comparable in primary and unpaired metastatic lung adenocarcinoma in pre-chemotherapy and postchemotherapy groups.

The prevalence of EML4-ALK, EGFR status and KRAS mutations in 208 Chinese patients with non-small cell lung cancer, is reported.

study anlayzed a mother and daughter with lung cancer with squamous differentiation; sequence analysis of EGFR on tumor-derived DNA revealed the copresence of 2 missense mutations in exon 18 [c.2155G>A, p.(G719S)] and in exon 20 [c.2327G>A, p.(R776H)

Epidermal growth factor receptor mutation is associated with lung carcinomas.

in a cohort of patients with lung adenocarcinomas, study found EGFR exon 20 insertions are a highly heterogeneous family of activating mutations with an incidence that is higher than previously reported

Report improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.

EGFR mutation status significantly affected the chemotherapy patterns in advanced non-small cell lung cancer .

EGFR mutations and ALK rearrangement is associated with resistance to EGFR tyrosine kinase inhibitors in lung cancer.

EGFR mutation is associated with response to therapy in lung cancer.

Epidermal growth factor receptor mutation is associated with lung carcinomas.

In patients with non-small cell lung cancer, EGFR mutant content was correlated with the response and prognosis of EGFR tyrosine kinase inhibitors.

Report mutation-specific immunohistochemistry, using optimized procedures, as a reliable prescreening test for detecting EGFR mutations in lung adenocarcinoma.

This study showed that patients with pulmonary adenocarcinoma and ILD had a lower probability of carrying tumor EGFR mutations.

EGFR mutation in Uighur lung adenocarcinoma patients (16.2%) is significantly lower than that in Han lung adenocarcinoma patients (45.7%).

Our study demonstrated that EGFR mutated Adenosquamous carcinoma of the lung had similar clinicopathological features as EGFR mutated adenocarcinoma

EGFR mutations are associated with papillary lung tumors.

exon 21 EGFR mutations are associated with response to therapy in lung adenocarcinoma.

Results ndicate the utility of serum DNA as a resource and pyrosequencing as a method for the detection of EGFR mutations in advanced non-small cell lung cancer (NSCLC).

EGFR mutations are associated with metastatic lung adenocarcinoma.

Resistance to EGFR-TKI develops within less than one year in EGFR-mutated lung cancer patients.

The most frequent activating EGFR mutations detected in non-small setting lung cancer are absent in penile cancer

The interplay between EGFR and AURKA provides an explanation for the difference in EGF dependency between EGFR-WT and EGFR-mutant cells and may provide a new therapeutic strategy for lung cancer patients carrying EGFR mutations.

EGFR gene amplification is associated with response to therapy in lung adenocarcinomas.

Germ line epidermal growth factor receptor T790M mutations concurrent with KRAS mutations are associated with lung cancer.

A high EGFR copy number may predict benefit from tyrosine kinase inhibitors treatment for non-small-cell lung cancer patients with wild-type EGFR.

EGFR mutant-lung adenocarcinoma with acquired resistance to EGFR-tyrosine kinase inhibitors responds poorly to radiotherapy for brain metastases.

EGFR mutations are not associated with tyrosine kinase inhibitors treatment efficacy in non-small cell lung cancer.

EGFR mutations are associated with lung adenocarcinoma.

EGFR mutations are associated with lung cancer.

Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients

EGFR mutation-specific antibodies could be an additional tool distinguishing primary versus metastatic carcinomas in the lung.

Data indicate that the epidermal growth factor receptor (EGFR) mutation status was not associated with disease-free survival or overall survival in resected lung adenocarcinomas.

lung cancer derived exosomes contain EGF receptor and can induce tolerogenic dendritic cells.

Serum CEA and CA242 levels are associated with mutations of the EGFR gene in patients with lung adenocarcinomas.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

miR-27a regulates MET, EGFR, and Sprouty2 in lung cancer.

Repeat biopsy identified pathological transformation to small cell lung cancers (SCLC) retaining the same EGFR mutation.

The mutations of EGFR and BRAF genes were not found in HER2-mutated patients with brain metastasis from non-small cell lung cancer.

Epidermal growth factor receptor mutations are more common among females, never-smokers, and patients with adenocarcinomas of the lung and patients with exon 18 mutations have a worse survival

EGFR mutations are associated with response to therapy in non-small-cell lung cancer.

EGFR mutations are associated with response to therapy in non-small cell lung carcinoma.

EGFR mutation is associated with response to treatment in non-small cell lung cancer.

HPV16/18 E6 may contribute in part to EGFR mutations in lung cancer, at least in the Taiwanese population.

Statistically significant differences were noted in the positive rates of EGFR genetic mutations in non-small cell lung cancer patients between Uygur and Han ethnic groups, with lower positive rates for the Uygur cases.

EGFR mutation is associated with response to erlotinib in non-small-cell lung cancer

Race was statistically significantly associated with EGFR mutational status in patients with non small cell lung cancer.

EGFR mutations are associated with lung cancer.

Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.

Epidermal growth factor receptor gene mutations are associated with response to therapy in non-small cell lung cancer.

EGFR activating mutations are associated with brain metastases in non-small lung cancer.

Report skeletal-related events in advanced lung adenocarcinoma patients with EGFR mutations in whom bone metastasis was present.

Report adiponectin levels in non-small lung cancer patients treated with EGFR tyrosine kinase inhibitors.

mutation is associated with improved survival time to platinum-based chemotherapy in patients with non-small-cell lung cancer

non-small cell lung cancer patients harboring rare mutations did not show consistent and favorable responses to EGFR TKI compared with those harboring classical mutations

Data suggest that Notch-1 might play a novel role in acquired resistance of non-small cell lung cancer to EGFR inhibitor gefitinib.

evaluated mutations in four driver genes, epidermal growth factor receptor (EGFR), Kirsten ras oncogene (KRAS), c-MET, and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), in Chinese lung adenocarcinoma patients

mutation of the EGFR gene is a positive prognostic marker in completely resected stage I non-small lung cancer

The frequencies of somatic EGFR, KRAS, and ALK gene abnormalities reflect the diverse ethnicity and smoking patterns of non-small-cell lung cancers patients in the United States.

study found that the frequency of EGFR mutations in lung adenocarcinomas among US Hispanics is similar to the frequency among non-Hispanic whites

EGFR mutation is associated with response to therapy in lung adenocarcinoma.

Data suggest subpopulations of lung adenocarcinoma cells containing mutations in EGFR undergo epithelial-to-mesenchymal transition, demonstrate high levels of basal autophagy, resist protein kinase inhibitors, and thrive under hypoxic conditions.

T790M mutation in EGFR is associated with response to therapy in Non-Small-Cell lung Carcinoma.

Exon 19 and 21 mutation in EGFR is associated with response to therapy in metastatic Non-Small-Cell lung Carcinoma.

EGFR mutations are associated with lung adenocarcinoma.

G719D+L861R mutation in EGFR is associated with response to therapy in Non-Small-Cell lung Carcinoma.

Integrin alpha2 beta1 and EGFR cooperatively promote higher invasiveness of ionizing radiation - survived lung cancer cells, mediated in part by the PI3K/Akt signaling pathway, and might serve as alternative targets in combination with radiotherapy.

EGFR mutation is associated with response to afatinib therapy in lung cancer

erlotinib and cetuximab treatment was associated with SD >/= six months/PR in five of 20 patients with non-small cell lung cancer (25%), including individuals with squamous histology, TKI-resistant EGFR mutations, and wild-type EGFR

For patients with lung adenocarcinoma harboring activating EGFR mutations treated with EGFR-TKIs, solid predominant subtype is a response predictor for EGFR-kinase inhibitors.

Presence of EGFR mutations in patients with lung adenocarcinoma correlates with lower lymph node stage and a greater number of metastatic lesions in the lung and brain.

CONCLUSION: EGFR is expressed non-small-cell lung carcinomas Further studies to unravel the predictors for acquired genetic alterations of EGFR are needed.

The observed benefit of addition of chemotherapy over TKI in EGFR mutation-positive group raises the question, can we offer the therapy of chemotherapy-TKI combination to EGFR mutation-positive lung cancer patients as shown in the present study.

in lung adenocarcinomas, KRAS mutations are prevalent in male smokers; EGFR mutations are associated with female sex, nonsmoking and lepidic and micropapillary growth; TTF1 has a role in survival; BRAF mutations have roles in survival

data on EGFR mutation status from a large German cohort of non-small cell lung cancer patients in daily clinical practice are in agreement with data from other populations around the world with regard to associations with gender, smoking habits and TTF1 expression

EGF receptor mutated lung cancers respond better to higher doses of gefitinib and develop resistance later than when a lower dose is employed.

Report analysis of EGFR mutations in non-small cell lung carcinomas.

Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.

EGFR mutations are associated with response to therapy in lung cancer.

findings show that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase proinflammatory cytokines; these findings indicate EGFR functions as an oncogene through non-cell-autonomous mechanisms

mutation of EGFR E21 is negatively correlated with TUBB3 gene expression in non-small cell lung cancer.

Found progressive loss of PTEN and increase in EGFR, TGF-alpha, P-AKT expression from benign samples to non small cell lung cancer. Changes were correlated to differentiation extent of cancer tissue, metastasis of lymph nodes and histological classification.

Sorafenib demonstrates clinical activity in non-small cell lung cancer , especially with wild-type EGFR

EGFR overexpression was observed in 47% of non-small-cell lung carcinoma patients and was significantly associated with squamous cell carcinoma.

EGFR mutation status is highly concordant between the primary non-small cell lung cancer and corresponding brain metastases

Data indicate that coexistence of EML4-ALK fusion or ALK copy number increase and EGFR, MET, and KRAS mutations in tumor tissue from two treatment-naive Chinese non-small cell lung cancer (NSCLC) patients.

overall genomic and transcriptional landscape of lung adenocarcinoma is affected, but only to a minor extent, by EGFR and KRAS mutation status

High coexpression of both EGFR and IGF1R is associated with non-small-cell lung cancer.

EGFR mutation is associated with response to therapy in non-small cell lung cancer.

EGFR mutation is not associated with gefitinib resistance in non-small cell lung cancer.

an EGFR mutation in exon 19 may have a role in improving survival and prognosis of lung adenocarcinoma after resection

DOK2 as a tumor suppressor in EGFR-mutant lung adenocarcinoma

Measuring plasma levels of miR-195 and miR-122 may especially be useful in EGFR mutant patients with lung adenocarcinoma

Rare EGFR-mutated non-small-cell lung cancer are heterogeneous, with drug resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to tyrosine kinase inhibitors.

Estimate the EGFR mutation incidence Polish non-small cell lung cancer patients.

direct sequencing overlooked EGFR mutation in a significant number of lung adenocarcinoma patients

These results suggest that co-inhibition of ROS1 and EGFR may be an effective strategy to combat resistance to targeted therapy in some ROS1 fusion-positive non-small cell lung cancer patients.

Report intratumoral distribution of EGFR-amplified and EGFR-mutated cells during the developmental process of lung adenocarcinoma.

our data suggest that castPCR is highly sensitive and specific to detect EGFR mutations in non-small-cell lung cancer clinical samples.

A high frequency of somatic mutations in p53 (44.3%; 43/97) and/or EGFR (51.5%; 50/97) resulted in a high discrimination rate of tumor clonality (77.3%; 75/97) in metachronous multiple lung cancers.

lung adenocarcinoma patients with an EGFR T790M mutation showed a more favorable prognosis.

EGFR mutations are associated with non--small-cell lung cancer.

EGFR mutation is associated with lung cancer.

Epidermal growth factor receptor mutation is associated with non-small cell lung cancer

the significant somatic EGFR alterations/mutations in lung adenocarcinoma (Review)

EGFR mutation is associated with response to chemotherapy in lung adenocarcinoma.

An uncommon insertion mutation in exon 19 of EGFR is associated with response to chemotherapy in lung adenocarcinoma.

EGFR mutation is associated with squamous cell lung carcinoma.

EGFR mutation ratios in primary tumors and metastatic tumors are different in lung adenocarcinoma.

in this work, we identified TPCA-1 as a direct dual inhibitor for both IKKs and STAT3, whereas treatment targeting EGFR only could not sufficiently repress NF-kappaB and STAT3 pathways for lung cancers harboring mutant EGFR

Wild-type EGFR versus mutated EGFR was associated with early progression. The presence of abdominal metastasis was independently associated with early progression in metastatic non-small-cell lung carcinoma receiving EGFR-TKI.

EGFR mutations are associated with advanced non-small-cell lung cancer of adenocarcinoma in Asian patients.

EGFR G719X and L861Q mutations are associated with response to therapy in non-small-cell lung cancer.

EGFR mutation is associated with brain metastasis in pulmonary adenocarcinomas.

EGFR mutations are associated with response to therapy in non-small-cell lung cancer.

EGFR exon 19 insertions is associated with response to gefitinib in lung cancer.

lung adenocarcinomas with EGFR exon 20 insertion mutations were present in a considerable proportion of patients, had distinct clinicopathologic characteristics, and had different pathway activation patterns compared to classic EGFR activating mutations.

First-line afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-positive advanced non-small cell lung cancer.

High EGFR gene copy number is associated with non-small cell lung cancer.

Major EGFR mutations and adenocarcinoma histology are independent predictors of better treatment outcome in patients with EGFR-mutant non-small cell lung cancer.

IGF1R activation is a molecular mechanism that confers acquired resistance to erlotinib in lung cancers with the wild-type EGFR

Frequencey of baseline EGFR T790M mutations and correlation with poor response to EGFR inhibitors in lung cancer.

Elevated serum CEA levels predict the presence of EGFR gene mutations in Chinese nonsmokers with pulmonary adenocarcinoma.

A gene polymorphism with lung cancer was found, and EGFR Short genotype of cytosine adenine repeat number polymorphism was significantly associated with an increased risk of lung cancer. [review]

SR48692 may inhibit non-small cell lung cancer cell proliferation in an EGFR-dependent mechanism.

In Malaysian patients with non- small cell lung cancer, the EGFR mutation rate was similar to that in other Asian populations.

EGFR activation is involved in the downregulation of miR-145 in lung cancer cells

EGFR mutation is associated with lung cancer.

genetic association study in population studied at academic medical center in Chicago: Data suggest that predominant subtype of lung adenocarcinoma is lepidic (44%; proposed IASLC/ATS/ERS classification) in patients with EGFR-mutant/deletions.

Activating mutations of EGFR were observed in 28.6% of adenosquamous lung carcinoma patients and included deletions of 15 base-pairs in exon 19 in three cases and substitution of L861Q with coexistence of G719X mutation in one non-smoking male patient.

EGFR exon 19 deletions were associated with lung cancer.

KLK6 promotes the proliferation of lung tumoral cells and restrains their apoptosis in vitro via ligand-dependent EGFR and was dependent on the protease-activated receptor 2.

Data indicate that metformin reverses epithelial-mesenchymal transition and decreases interleukin-6 signaling in EGFR-TKI-resistant lung cancer cells.

Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma.

No association of beclin 1 with EGFR mutation was found (P > 0.05) in non-small cell lung cancer.

EGFR gene T790M mutations are associated with lung cancer.

EGFR mutation is associated with treatment response in non-small-cell lung cancer.

Germline EGFR T790M mutation is associated with metastasis in lung adenocarcinoma.

EGFR exon 19 insertions are sensitive to gefitinib treatment in lung cancer.

In lung adenocarcinomas, positive and partial positive TTF-1 expression has a significant positive correlation with EGFR mutations(exon 19 and 21).

EGFR mutation is associated with treatment efficacy in non-small cell lung cancer.

No significant associations were found among GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in advanced non-small cell lung cancer with unknown EGFR mutation.

To study the prognostic factors influencing survival after recurrence, EGFR mutations were prospectively evaluated in 594 patients who underwent curative surgical resection for pulmonary adenocarcinoma.

EGFR mutation detection is associated with non-small cell lung carcinoma.

lung adenocarcinoma with morule-like components is a distinct unfavorable prognostic and predictor for EGFR mutation.

EGFR/p53 mutations were associated with lung adenocarcinomas tumor size >1 cm. EGFR mutation was a predictor of EGFR TKI response in relapsed patients.

EGFR mutation is associated with drug resistance in non-small cell lung cancer.

Aromatase is a candidate prognostic factor in patients with lung adenocarcinoma, especially in those with EGFR mutations, and may also be a beneficial therapeutic target in those patients.

Results show that minor EGFR T790M mutations were present in 13% of EGFR-TKI-naive surgically resected lung adenocarcinomas and were associated with drug-sensitive EGFR mutations.

EGFR and KRAS mutations were present in adenocarcinoma of the lung but not squamous tumors.

In a cohort with non-small cell lung cancer, the mutation rates in EGFR exons 19 and 21 were 23.2% and 14.9%, respectively, with both in 3.81%. mutation was more common in non-smokers than smokers, and in adenocarcinoma more than squamous cell carcinoma.

EGFR mutation is associated with response to therapy in lung adenocarcinoma.

EGFR mutations were found in 2.8% of lung adenocarcinomas with nodular ground-glass opacity.

Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.

The EGFR-GEP100-Arf6 axis affected the prognosis of patients with primary lung adenocarcinoma.

A prevalence of EGFR mutations in small cell lung cancer is rare, and occurs most frequently in females and nonsmokers.

High EGFR expression is associated with non-small cell lung cancer.

EGFR mutations are associated with lung adenocarcinomas.

EGFR gene mutations and the EML4-ALK fusion gene were detected in 92 lung adenocarcinoma patients in China.

Findings suggest that adding chloroquine to EGF receptor (EGFR) and AKT2 inhibition has the potential to improve tumor responses in EGFR M+ non-small cell lung cancer (NSCLC).

Ten patients with metastatic non-small cell lung cancer harboring an activating epidermal growth factor receptor mutation were included in this prospective observational study

The frequency and characteristics of EGFR gene mutation in Turkish non-small cell lung cancer patients

In advanced non-small-cell lung cancer, folate receptor alpha (FRA) and EGFR are frequently coexpressed, but FRA and EGFR protein levels did not statistically correlate with each other

The mutant allele frequency may be a potential predictive factor of tyrosine kinase inhibitor treatment efficacy in patients with lung adenocarcinoma carrying the L858R mutation of the EGFR.

We sought to investigate whether mucinous features, such as signet-ring cell feature and extracellular mucin, are associated with EGFR and KRAS mutations in patients with lung adenocarcinoma

Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma

Oncogenic EGFR upregulated mir31 in lung carcinogenesis.

High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line non-small cell lung cancer

Positive EGFR mutations were shown to be associated with a better response to Docetaxel previously treated with a Paclitaxel-Platinum doublet for the treatment of Non-Small-Cell lung cancer in the Mexican population.

EGFR gene mutations occurred more frequently in adenocarcinoma patients particularly with accompanying expression of TTF1 in non-small cell lung cancer.

EGFR mutation is associated with non-small cell lung cancer.

EGFR mutation is associated with treatment response in non-small-cell lung cancer.

DNa mutational analysis in lebanese population shows that mutations of EGFR and KRAS are present in 8.5% and 37.7% respectivement in lung adenocarcinoma.

mutation rate in domain of EGFR gene in investigated lung cancer population is in range with reported data in Caucasian race.

Assessment of EGFR mutations in circulating tumor cell preparations from non-small-cell lung carcinoma patients is a very sensitive and specific diagnostic tool.

Theanine derivatives effectively suppress the growth of lung cancer cells in vitro, ex vivo and in vivo by targeting EGFR/VEGFR-Akt/NF-kappaB pathways.

Epidermal growth factor receptor exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

Study shows that EGFR mutation is detected in 47.7% of non-small-cell lung cancer and seems to be more frequent in patients 80 years and older.

EGFR mutation is associated with lung adenocarcinoma.

EGFR mutations were not a prognostic factor in patients with surgically resected non-small cell lung cancer. (Meta-analysis)

Deletion of Ctnnb1 significantly inhibits EGFR mutation dependent human lung tumor formation in mice.

Data indicate that the efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation does not differ according to their body surface area (BSA).

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been shown to improve the prognosis of EGFR-mutated (exon 19/21) non-small cell lung carcinoma (NSCLC). Positive EGFR mutation status is associated with NSCLC in non-smokers.

Del 19 and L858R are the most frequent mutations in Pakistani lung adenocarcinoma patients.

There was a positive association between EGFR mutation and the presence of malignant pleural effusion in lung cancer.

Neurotensin and its receptor NTSR1 causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung adenocarcinomas, confirming responsiveness to erlotinib.

Results indicate that protein tyrosine phosphatase non-receptor type 3 (PTPN3) may act as a tumor suppressor in lung cancer through its modulation of epidermal growth factor receptor (EGFR) signaling.

EGFR gene mutation status is significantly associated with serum carcinoembryonic antigen (CEA) status in advanced lung adenocarcinmoas;however, serum CEA is not an ideal predictor for EGFR mutation

immunohistochemistry with the novel mutation-specific antibody could be used as a screening method to assess the EGFR L858R mutation status in primary lung adenocarcinoma.

Suggest potential applications for the noninvasive detection of E746_A750del mutations in plasma samples from non-small cell lung cancer patients.

In our series of Caucasian women with advanced adenocarcinoma of the lung EGFR mutations seem to be associated with lower benefit from first-line platinum-based chemotherapy .

Our results indicated that the efficacies and outcomes of pemetrexed treatment in advanced lung adenocarcinoma patients with EGFR activating mutations were similar to those in patients with EGFR-wild-type genotype.

Patients with EGFR-mutated non-small-cell lung cancer were more likely to develop brain metastases, but apparently also survived longer after brain metastases

Either ligand-independent or ligand-induced EGFR phosphorylation was inhibited in lung cancer cells that strongly expressed DDX3X.

EGFR mutation is associated with non-small-cell lung cancer.

The BIM polymorphism is not associated with EGFR mutant lung cancer.

Demonstrate that Mig-6 could reverse gefitinib resistance through inhibition of EGFR/ERK pathway in non-small cell lung cancer cell lines.

Date indicate there were no significant differences between the lung cancer patients with epidermal growth factor receptor (EGFR) exon 19 and 21 mutations for overall survival.

No difference in gender and age regarding EGFR mutation status was observed on cytological as well as on histological material in patients with non-small cell lung cancer

the clinical profile of EGFR-mutant lung cancer carrying a pretreatment nongermline T790M mutation was similar to that of sensitive EGFR-mutant lung cancer, except for an overrepresentation of never-smokers and brain metastasis

The presence of EGFR activating mutations should be included as an index in the prognostic models for lung adenocarcinoma patients with brain metastasis.

EGFR-activating mutations are associated with response to therapy in non-small-cell lung cancer.

First- or second-line afatinib demonstrated preliminary activity and manageable safety in EGFR FISH-positive patients with advanced non-small-cell lung cancer.

tumor-suppressive miR206 inhibited dual signaling networks activated by MET and EGFR in lung squamous cell carcinoma.

The presence of well-differentiated components in lung adenocarcinoma, such as lepidic, papillary and acinar, indicates a higher EGFR mutation rate, while the solid and mucinous component indicate a lower EGFR mutation rate.

Results suggest that GPCR transactivation of the EGFR may play an important role in lung cancer cell proliferation. [review]

EGFR mutations are closely associated with a high response rate to lung cancer treatment with an EGFR tyrosine kinase inhibitor.

EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity

EGFR mutations are associated with response to chemotherapy in lung adenocarcinoma.

Erlotinib/capecitabine chemotherapy was significantly better in older Chinese patients with advanced Adenocarcinoma of the lung with EGFR mutations.

EGFR mutation status was associated with lepidic dominant histologic subtype of lung adenocarcinomas.

Our findings support the genetic heterogeneity of non-small cell lung cancer in Latin America, confirming that the frequency of EGFR mutations is intermediate between that observed in the Asian and Caucasian populations.

EGFR gene mutation is associated with non small cell lung carcinoma.

EGFR is overexpressed in Bruneian lung cancer patient.

Results show that suppression of EGFR membrane recycling by SNX1 appears to be critical for the activation of EGFR /PI3K/AKT signaling pathway in human lung cancer cells.

Letter/Case Report: transformation to squamous cell carcinoma after tyrosine protein kinase resistance in EGFR-mutated non-small lung carcinoma.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.

These data suggested that Ets-2, a genuine cancer-specific transcription factor, is actively involved in EGFR kinase-induced hTERT overexpression pathway in lung cancer cells.

Brain metastases are frequent in advanced EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

EGFR mutations are associated with non-small cell lung cancer.

EGFR gene mutations are associated with response to chemotherapy in non-small cell lung cancer.

The lack of response to EGFR inhibitors in EGFR mutated lung cancer may indicate that tumor differentiation affects tumor dependency on EGFR as a driver oncogene.

mutations associated with pneumonic-type lung cancer relative to other lung cancer

miR-129, EGFR, and MMP9 appear to be promising therapeutic targets for preventing the metastasis of non-small cell lung cancer

Report inhibition of non-small cell lung cancer growth by a novel small molecular inhibitor of EGFR.

Results show that inhibition of the Shp2 PTP activity impairs mutant EGFR signaling and suppresses EGFRL858R-driven lung adenocarcinoma.

MIG6 is a potent tumor suppressor for mutant EGFR-driven lung tumor initiation and progression in mice and provides a possible mechanism by which mutant EGFR can partially circumvent this tumor suppressor in human lung adenocarcinoma.

Results show how GPRC5A deficiency leads to dysregulated EGFR and STAT3 signaling and lung tumorigenesis.

RB is lost in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

EGFR mutation was associated with lung cancer in never-smoker Asian females.

estimated prevalence of sensitizing EGFR mutations (exon 19 del, exon 21 L858R) in an unselected samples of newly diagnosed advanced non-small cell lung cancer patients in Spain

The epidermal growth factor receptor (EGFR) is a common driver molecule in non-small cell lung cancer (NSCLC), making it an attractive target for the development of novel therapies in the current era of personalized medicine.

The study revealed statistically significant associations of EGFR gene mutations with gender, smoking and stage of lung adenocarcinoma in residents of southern Russia.

In multivariable analyses, in both patients with EGFR-mutant and KRAS-mutant lung adenocarcinomas, advanced stage at the time of diagnosis was found to be independently associated with shorter survival.

CHCHD2 and EGFR protein expression levels were positively correlated and upregulated relative to normal lung in non-small cell lung carcinoma tumor-derived xenografts.

EGFR-activating mutation is associated with the treatment outcome of first-line chemotherapy in advanced non-small cell lung cancer patients.

KRAS and EGFR co-mutation was detected in one case. PPMA patients with ALK rearrangements or KRAS mutation represent a unique subtype in Non-Small-Cell lung Carcinoma

MET gene may be useful in predicting shortened PFS and OS after Gefitinib treatment in lung adenocarcinoma. The correlation between MET gene status and clinical outcomes for EGFR-TKI should be further evaluated using large scale samples.

Results showed that EGFR mutation was detected in 17.2% of Chinese patients with pure squamous-cell lung cancer, especially in females indicating the importance of this mutation in tailoring a personalized therapy with tyrosine kinase inhibitors.

EGFR mutation is associated with response to treatment in nonsmall-cell lung cancer.

AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors.

Report documents that half of T790M-positive EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance.

EGFR and KRAS mutation were associated with non-small cell lung carcinoma.

The frequency of EGFR mutations is 63% in the southern Taiwanese lung adenocarcinoma patients.

DNA mutational analysis of EGFR mutation is a reliable test for diagnosing lung adenocarcinoma.

EGFR mutation is associated with response to chemotherapy in metastatic pulmonary adenocarcinoma.

mutational status is a prognostic factor for survival after recurrence in patients with resected lung adenocarcinoma

EGFR mutations are associated with response to therapy in non-small cell lung cancer patients.

Upregulation of EGFR and c-Met is associated with epithelial mesenchymal transition in response to increased matrix rigidity in pulmonary adenocarcinoma.

Validate a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations in non-small cell lung carcinoma.

investigated the involvement of the RAS/MEK/ERK and PI3K/AKT/mammalian target of rapamycin (mTOR) pathways on metabolic alteration in lung adenocarcinoma cell lines with activating EGFR mutations

Nickel accumulation in lung tissues is associated with EGFR mutations, miR-21 expression, and a poor outcome in lung cancer never-smoking patients.

Exon 19 deletion in EGFR gene is associated with response to therapy in non-small cell lung cancer patients.

In pretreated elderly patients with advanced or recurrent EGFR-wild type non-small cell lung cancer, daily oral erlotinib was well tolerated.

In transgenic mice programmed to express both mutant oncogenes in the lung epithelium, the resulting tumors express either the KRAS, or the EGFR oncogene.

EGFR-mutant allele-specific imbalance is a significant event in non-small cell lung cancer, specifically associated with EGFR exon 19 deletions

among lung adenocarcinoma patients with EGFR mutations, those mutated at exon 19 had the highest incidence of brain metastasis(BM); patients with EGFR mutations are more likely to develop heterochronous BM

Afatinib administration in non small cell lung cancer patients with EGFR mutation were successful.

The therapeutic activity of TUSC2 could extend the use of erlotinib to lung cancer patients with wildtype EGFR.

Exon 19 deletion in EGFR is an independent prognostic factor in Brain metastasis from non-small-cell lung cancer . It should be integrated into the prognostic scoring classification system for NSCLC.

Afatinib significantly improved PFS versus cisplatin/pemetrexed in Japanese EGFR mutation-positive lung adenocarcinoma patients.

EGFR mutation is associated with response to chemotherapy in non-small cell lung cancer.

The majority of patients with advanced lung adenocarcinomas harboring EGFR exon20ins do not respond to EGFR tyrosine kinase inhibitors therapy

Our study suggests that telomerase (TERT)and telomere function may be essential for carcinogenesis of EGFRmut(+) non-small cell lung cancer

increased expression of Flot-2 and EGFR in non-small cell lung cancer patients is inversely proportional to the disease prognosis.

Suggest different miRNA expression between EGFR mutation group and wild type group inlung adenocarcinoma.

non-small-cell lung cancer (NSCLC) patients with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) could benefit from the same TKI therapy through months to years of disease control.

EGFRL858R mutation in circulating DNA is a negative prognostic biomarker in non-small cell lung carcinoma patients.

Overexpression of miR-200a in non-small lung cancer cells significantly downregulates both EGFR and c-Met levels and severely inhibits cell migration and invasion.

rare mutation in a patient with lung adenocarcinoma successfully treated with gefitinib

lung cancers harboring exon 18 mutations should not be overlooked in clinical practice. These cases can be best treated with afatinib or neratinib.

EGFR mutations are associated with lung cancer.

mutations are associated with survival outcomes in advanced lung cancer

Tyr1068-phosphorylated EGFR predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Data report rare EGFR mutations in patients with non-small cell lung cancer of unknown clinical significance.

data suggest one-step screening platform for KIF5B-RET as well as EGFR, K-RAS, ALK oncogenic mutations be necessary for lung adenocarcinoma patients

EGFR T790M is associated with drug resistance in Non-Small-Cell lung Carcinoma.

Results found that plasma soluble EGFR was significantly decreased in the non-small cell lung cancer (NSCLC) patients group as compared to the control group, and inhibits growth and migration of NSCLC cells in vitro.

Data suggest that Src kinases inhibitors may act with different mechanisms in non-small cell lung cancer (NSCLC) depending on EGF receptor (EGFR)/Ras protein (Ras) mutational profile.

A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas.

Epidermal Growth Factor Receptor mutations in Serum is associated with response to Erlotinib for Advanced Non-Small-Cell lung cancer.

single EGFR exon 18 mutations may be an indicator of poor prognosis of lung adenocarcinoma compared with complex EGFR exon 18 mutations or classic mutations

EGFR mutations are indicators of malignant transition in the progression to lung adenocarcinoma.

EGFR mutation is associated with response to chemotherapy in Non-Small-Cell lung Carcinoma.

EGFR and KRAS mutations are associated with ALK-Positive lung Adenocarcinomas.

EGFR mutations are associated with Non-Small-Cell lung cancer.

The aim of this study was to explore epidermal growth factor receptor (EGFR) gene amplification and its relationship with cancer invasion and metastasis in non-small cell lung cancer

21 novel somatic variants in exons 18-21 of EGFR in adult Argentinean patients affected with non-small cell lung cancer were reported

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-mutations in Mixed lung Adenocarcinoma

Higher cell free EGFR mRNA expression may play an important role in causing distant metastases and reducing overall survival of Non-Small Cell lung cancer patients in the Indian population.

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.

The Emergent Landscape of Detecting EGFR mutations Using Circulating tumor DNA in lung cancer.

This study demonstrates that high serum COX-2 levels may indicate EGFR mutations in non-small cell lung cancer.

study emphasized that the AXL and EGFR receptor tyrosine kinases were coexpressed in a subgroup of treatment-naive lung adenocarcinomas with or without EGFR mutations

EGFR and KRAS mutations were low in lung squamous cell carcinomas, and had no significant correlation with clinical features.

Mitochondrial translocation of EGFR may enhance cancer invasion and metastasis through regulating mitochondria dynamics in non-small cell lung carcinoma.

Data identified several cases of complex EGFR mutations, and concomitant EGFR mutations and ALK rearrangements in non-small cell lung cancer

in non-small cell lung carcinoma patients, EGFR mutations were detected in exon 19 in 32 patients, exon 20 in 16, and exon 21 in 15; no mutations were observed in exon 18

This analysis is the first to reveal the relationship between EGFR mutation status and the spatial distribution of brain metastases of lung cancer.

EGFR mutation is associated with response to chemotherapy in Non-Small Cell lung cancer.

Chromogenic Assay for lung cancer-Related EGFR Exon 19 Hotspot Deletion mutations.

Suggest that IGF1R plays an important role in acquired drug resistance against EGFR-TKIs by inducing epithelial mesenchymal transformation in non-small cell lung cancer.

COPD-related NSCLC patients exhibited low prevalences of EGFR mutations and ALK rearrangements compared with the non-COPD group. Further studies are required regarding the molecular mechanisms underlying lung cancer associated with COPD

EGFR knockdown led to upregulation of NKX2-1, suggesting a negative feedback loop. combined knockdown of NKX2-1 and EGFR in NCI-H1819 lung cancer cells reduced cell proliferation more than knockdown of either alone.

In lung adenocarcinomas, EGFR mutation was higher in female and non-smoking patients, KRAS mutation only in patients with wild-type EGFR gene was higher.

we identify that EGFR mutations might associate with more aggressive tumor progression than the wild types in non-small-cell lung cancer

mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant non-small-cell lung cancer.

lung adenocarcinomas with L858R mutation, rather than exon 19 deletion or wild-type EGFR gene, prefer to locate over the upper lungs

EGFR exon 19 deletions were associated with better outcomes in non-small cell lung cancer, despite a higher percentage of brain metastases

Overexpression of wildtype EGFR is tumorigenic in non-small cell lung cancer.

EGFR kinase domain mutation is associated with response to chemotherapy in lung cancers.

Data indicate that epidermal growth factor receptor (EGFR) mutant lung cancer as a vitamin D-responsive disease and diet-derived 25-hydroxyvitamin D3 (25D3) as a direct vitamin D receptor (VDR) agonist and therapeutic agent.

Epidermal Growth Factor Receptor mutation is associated with response to chemotherapy in Small Cell lung cancer.

case report and case series on germline mutations in patients with lung adenocarcinoma

DNA sequencing detected EGFR mutations with high frequency and revealed a broad spectrum of mutation type in Vietnamese patients with non-small cell lung cancer

EGFR mutation is associated with response to chemotherapy in lung cancer.

plasma EGFR mutation status before tyrosine kinase inhibitors therapy might be of prognostic significance for TKIs-treated non-small cell lung cancer patients with tumor tissue EGFR mutation

Data show that Prolyl isomerase Pin1 is expressed in an epidermal growth factor receptor (EGFR)-mutant lung cancer tissue that has undergone partial epithelial-mesenchymal transition (EMT) and acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).

EGFR mutations are associated with treatment response in Non-small cell lung cancer.

EGFR mutation is associated with Small Cell lung cancer Transformation.

Noninvasive monitoring of the predominance of tumors harboring the secondary T790M mutation in the activating mutation in EGFR gene is necessary for precise and effective treatment of lung adenocarcinoma.

EGFR mutation is associated with non small cell lung cancer.

EGFR mutations are associated with non-small-cell lung cancer.

patients with wild-type EGFR might not benefit from first-line treatment of advanced Non-Small-cell lung cancer with gefitinib

The EGFR rs6965469 and rs763317 polymorphisms may be risk factors for lung cancer.

ATM inhibition may facilitate the gefitinib-dependent repression of the phosphorylation of EGFR and/or its downstream factors, to exert anticancer effects against non-small-cell lung cancer cells with the sensitive EGFR mutation

EGFR SNPS -216G>T, -191C>A, and 181946C>T were measured in Serbian non-small cell lung cancer (NSCLC) patients,compared controls. There was a significant association between -216GG genotype and NSCLC patients among smokers. Carriers of -216GG genotype had a higher risk than noncarriers (GT and TT) for developing NSCLC.

EGFR mutation is associated with lung adenocarcinomas.

Epidermal Growth Factor Receptor mutation is associated with response to therapy in Non-small Cell lung cancer.

Results report that EGFR expression is significantly increased in tumors of lung adenocarcinoma patients and is negatively correlated with the expression of DEPTOR. The study also study uncovers the important inhibitory role of DEPTOR in lung adenocarcinoma progression and reveals a novel mechanism that EGFR downregulates DEPTOR expression to facilitate tumor growth.

EGFR mutation is associated with non-small cell lung cancer.

EGFR mutation is associated with non-small cell lung cancer.

EGFR mutation is associated with lung cancer.

These findings suggest that ezrin-EGFR interaction augments oncogenic functions of EGFR and that targeting ezrin may provide a potential novel approach to overcome erlotinib resistance in non-small cell lung cancer cells

mutation in patients with EGFR is a strong factor with which to predict outcomes in patients who received receptor tyrosine kinase inhibitors and approximately 70%-80% of patients with EGFR-mutant lung cancer initially respond to EGFR TKI therapy.

High EGFR expression is associated with lung cancer.

The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in non-small cell lung cancer (NSCLC). EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation

EGFR point mutations are associated lung cancer.

Studies indicate the role of tyrosine kinase inhibitors (TKIs) in EGFR non-mutated non-small-cell lung cancer (NSCLC) patients.

The Q787Q EGFR polymorphism allows stratifying lung squamous cell carcinoma patients and could be an independent prognostic marker, particularly among those in stages I and II.

Pretreatment nutritional status is a prognostic marker in EGFR mutated non-small cell lung carcinoma patients treated with protein kinase inhibitors.

The study found different epidermal growth factor receptor mutation status between different lesions in lung adenocarcinoma presenting as multiple ground-glass opacity lesions.

heterogeneous EGFR mutations are expressed in micropapillary component of lung adenocarcinomas

the results of this study highlight an important role for miR-218-5p in the regulation of epidermal growth factor receptor in non-small cell lung cancer

Forty-nine paired tissues with both primary adenocarcinoma of lung and matched brain metastasis were collected. Thirteen patients (26.5%) were discordant for the status of EGFR between primary and metastatic sites. K-ras gene could be checked in paired specimens from 33 patients, thirteen patients (39.6%) were discordant for the status of K-ras.